Manish A. Shah, MD, discusses the results from the randomized phase III GAMMA-1 trial looking at andecaliximab in patients with untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Manish A. Shah, MD, FASCO
Articles by Manish A. Shah, MD, FASCO
